Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | BRAF | P15056 | 1/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | MALT1 | Q9UDY8 | 9/20 | 0.42 |
| ▸ | CCR1 | P32246 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2858034 | 0.88 | BRAF (0.43) | KDM4EALDH1A1BRAFNR1H4MAPT | |
| SCHEMBL2852818 | 0.82 | NPC1 (0.50) | KDM4EALDH1A1BRAFNR1H4MAPT | |
| SCHEMBL13513708 | 0.82 | KDM4E (0.53) | KDM4EALDH1A1BRAFMAPTMALT1 | |
| SCHEMBL2857034 | 0.82 | KDM4E (0.62) | KDM4EALDH1A1BRAFNR1H4MAPT | |
| SCHEMBL2850892 | 0.81 | NR1H4 (0.53) | KDM4EALDH1A1BRAFNR1H4MAPT | |
| SCHEMBL14539344 | 0.81 | KDM4E (0.52) | KDM4EALDH1A1BRAFNR1H4MAPT | |
| SCHEMBL14258157 | 0.79 | KEAP1 (0.50) | KDM4EALDH1A1BRAFNR1H4MAPT | |
| SCHEMBL13513752 | 0.79 | BRAF (0.49) | KDM4EALDH1A1BRAFNR1H4MAPT | |
| SCHEMBL4882354 | 0.79 | NPC1 (0.49) | KDM4EALDH1A1BRAFNR1H4MAPT | |
| SCHEMBL2850859 | 0.78 | KEAP1 (0.51) | KDM4EALDH1A1BRAFNR1H4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | ICAGEN, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| US-7223782-B2 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | SCN3A, TRPV3, HCN3 | KDM4E 2869/4885ALDH1A1 3589/4885BRAF 738/4885 |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | SCN3A, TRPV3, HCN3 | KDM4E 2869/4885ALDH1A1 3589/4885BRAF 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.